Form D · Other

Gaingels Trojan Bio LLC

Burlilngton, VT · CIK 0001963198

Offering snapshot reported Nov 20, 2023 · SEC filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Nov 20, 2023	Initial	$162,766	No comparison	7	SEC filing

Source: Form D, filed Nov 20, 2023. Minimum accepted may differ from a standard advertised minimum.

The linked fund shows its most recently reported ADV details.

Matched by reported Form D file number

Investment adviser: GAINGELS VENTURES LLC

Reported in Form ADV on Mar 31, 2026. Fund assets and beneficial owners measure different things from Form D sales and investors.

Fund administrator GAINGELS INC NEW YORK, New York, United States Investor statements: No (provided to no investors) Related to adviser: No

Custodian SILICON VALLEY BANK SANTA CLARA, California, United States Related to adviser: No

Provider details

Filing source

Form ADV 2082471 · Mar 31, 2026 · Schedule D 7.B.(1), fund 805-2036033283

Official IAPD profile (latest public filing). Values are the most recently reported in our imported data; the public profile may show a newer filing.

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
David Beatty	Executive

Address:

C/O Gaingels Management Llc 3 Main Street Suite 214
Burlilngton, VT, 05401